BA 1302
Alternative Names: BA-1302Latest Information Update: 31 Mar 2023
At a glance
- Originator Shandong Boan Biotechnology
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 24 Feb 2023 Preclinical trials in Breast cancer in China (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)
- 24 Feb 2023 Preclinical trials in Colorectal cancer in China (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)
- 24 Feb 2023 Preclinical trials in Non-small cell lung cancer in China (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)